Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+10.9M
-
Total reported value, excl. options
-
$84M
-
Value change
-
+$17.8M
-
Put/Call ratio
-
1.31
-
Number of buys
-
62
-
Number of sells
-
-38
-
Price
-
$1.69
Significant Holders of ImmunityBio, Inc. - COM (IBRX) as of Q3 2023
152 filings reported holding IBRX - ImmunityBio, Inc. - COM as of Q3 2023.
ImmunityBio, Inc. - COM (IBRX) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (14.7M shares), BlackRock Inc. (10.8M shares), ARMISTICE CAPITAL, LLC (3.48M shares), GEODE CAPITAL MANAGEMENT, LLC (2.81M shares), STATE STREET CORP (2.72M shares), CREDIT SUISSE AG/ (1.53M shares), JPMORGAN CHASE & CO (1.45M shares), NORTHERN TRUST CORP (1.15M shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1.05M shares), and NATIONAL BANK OF CANADA /FI/ (699K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.